rofecoxib has been researched along with Pyrexia in 7 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " The role of COX-2 in the genesis of fever in monkeys and humans was examined with use of the specific COX-2 inhibitor rofecoxib." | 9.09 | Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans. ( Adcock, S; Bachmann, KA; Chan, CC; Cohen, RA; Davidson, MH; Dobratz, D; Gertz, BJ; Grasing, K; Hedges, J; Jones, TM; McBride, KJ; Moritz, C; Mukhopadhyay, S; Schwartz, JI, 1999) |
| " The role of COX-2 in the genesis of fever in monkeys and humans was examined with use of the specific COX-2 inhibitor rofecoxib." | 5.09 | Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans. ( Adcock, S; Bachmann, KA; Chan, CC; Cohen, RA; Davidson, MH; Dobratz, D; Gertz, BJ; Grasing, K; Hedges, J; Jones, TM; McBride, KJ; Moritz, C; Mukhopadhyay, S; Schwartz, JI, 1999) |
| " Thus, physiological and pathophysiological roles of COX-2 were considered from the standpoint of clinical effects of the two latest COX-2 selective inhibitors, celecoxib and rofecoxib, on inflammation, pain, fever and colorectal cancer together with their adverse effects on gastrointestinal, renal and platelet functions; and the usefulness and limits of COX-2-selective inhibitors were discussed with the trends of new NSAIDs development." | 4.81 | [Cyclooxygenase (COX)-2 selective inhibitors: aspirin, a dual COX-1/COX-2 inhibitor, to COX-2 selective inhibitors]. ( Nakamura, H, 2001) |
| "We studied the interaction of S-methylisothiourea (a selective inducible nitric oxide synthase inhibitor) with rofecoxib (selective cyclooxygenase-2 inhibitor) and mefenamic acid (non-selective cyclooxygenase inhibitor) in Brewer's yeast-induced pyrexia in mice by isobolographic analysis." | 3.73 | Interaction between inhibitors of inducible nitric oxide synthase and cyclooxygenase in Brewer's yeast induced pyrexia in mice: an isobolographic study. ( Bhat, AS; Krishna, V; Kumar, D; Prakash, VR; Tandan, SK, 2005) |
| "Neoplastic fever is relatively common in cancer patients." | 2.71 | Cyclo-oxygenase II inhibitors in the treatment of neoplastic fever. ( Kathula, SK; Koduri, J; Polenakovik, H; Shah, K, 2003) |
| " Both exhibit good oral bioavailability and are potent in standard models of pain, fever, and inflammation yet have a much reduced effect on the GI integrity of rats compared to standard nonsteroidal antiflammatory drugs." | 1.30 | 2,3-Diarylcyclopentenones as orally active, highly selective cyclooxygenase-2 inhibitors. ( Black, WC; Brideau, C; Chan, CC; Charleson, S; Chauret, N; Claveau, D; Ethier, D; Gordon, R; Greig, G; Guay, J; Hughes, G; Jolicoeur, P; Leblanc, Y; Nicoll-Griffith, D; Ouimet, N; Prasit, P; Riendeau, D; Visco, D; Wang, Z; Xu, L, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Black, WC | 2 |
| Brideau, C | 2 |
| Chan, CC | 3 |
| Charleson, S | 2 |
| Chauret, N | 1 |
| Claveau, D | 1 |
| Ethier, D | 1 |
| Gordon, R | 2 |
| Greig, G | 1 |
| Guay, J | 1 |
| Hughes, G | 2 |
| Jolicoeur, P | 1 |
| Leblanc, Y | 1 |
| Nicoll-Griffith, D | 1 |
| Ouimet, N | 1 |
| Riendeau, D | 2 |
| Visco, D | 1 |
| Wang, Z | 2 |
| Xu, L | 1 |
| Prasit, P | 2 |
| Cromlish, W | 1 |
| Grimm, EL | 1 |
| Leger, S | 1 |
| Li, CS | 1 |
| Thérien, M | 1 |
| Xu, LJ | 1 |
| Kathula, SK | 1 |
| Shah, K | 1 |
| Polenakovik, H | 1 |
| Koduri, J | 1 |
| Bhat, AS | 1 |
| Tandan, SK | 1 |
| Kumar, D | 1 |
| Krishna, V | 1 |
| Prakash, VR | 1 |
| Okumura, T | 1 |
| Murata, Y | 1 |
| Hizue, M | 1 |
| Matsuura, T | 1 |
| Naganeo, R | 1 |
| Kanai, Y | 1 |
| Murase, A | 1 |
| Sakakibara, A | 1 |
| Fujita, I | 1 |
| Nakao, K | 1 |
| Schwartz, JI | 1 |
| Mukhopadhyay, S | 1 |
| McBride, KJ | 1 |
| Jones, TM | 1 |
| Adcock, S | 1 |
| Moritz, C | 1 |
| Hedges, J | 1 |
| Grasing, K | 1 |
| Dobratz, D | 1 |
| Cohen, RA | 1 |
| Davidson, MH | 1 |
| Bachmann, KA | 1 |
| Gertz, BJ | 1 |
| Nakamura, H | 1 |
1 review available for rofecoxib and Pyrexia
| Article | Year |
|---|---|
[Cyclooxygenase (COX)-2 selective inhibitors: aspirin, a dual COX-1/COX-2 inhibitor, to COX-2 selective inhibitors].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Clinical Trials as Topic; Colo | 2001 |
2 trials available for rofecoxib and Pyrexia
| Article | Year |
|---|---|
Cyclo-oxygenase II inhibitors in the treatment of neoplastic fever.
Topics: Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose-Response Relationship | 2003 |
Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans.
Topics: Administration, Oral; Analysis of Variance; Animals; Body Temperature; Cyclooxygenase 2; Cyclooxygen | 1999 |
4 other studies available for rofecoxib and Pyrexia
| Article | Year |
|---|---|
2,3-Diarylcyclopentenones as orally active, highly selective cyclooxygenase-2 inhibitors.
Topics: Analgesics, Non-Narcotic; Animals; Arthritis, Experimental; Biological Availability; Carrageenan; Ce | 1999 |
3,4-Diaryl-5-hydroxyfuranones: highly selective inhibitors of cyclooxygenase-2 with aqueous solubility.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Chemical Phenomena; Chemi | 2003 |
Interaction between inhibitors of inducible nitric oxide synthase and cyclooxygenase in Brewer's yeast induced pyrexia in mice: an isobolographic study.
Topics: Animals; Body Temperature; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Interac | 2005 |
Pharmacological separation between peripheral and central functions of cyclooxygenase-2 with CIAA, a novel cyclooxygenase-2 inhibitor.
Topics: Animals; Brain; Carrageenan; Celecoxib; Chlorobenzoates; Cyclooxygenase 1; Cyclooxygenase 2; Cycloox | 2006 |